Advanced

Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene.

Mulder, Hindrik LU ; Nagorny, Cecilia LU ; Lyssenko, Valeriya LU and Groop, Leif LU (2009) In Diabetologia 52. p.1240-1249
Abstract
Melatonin is a circulating hormone that is primarily released from the pineal gland. It is best known as a regulator of seasonal and circadian rhythms; its levels are high during the night and low during the day. Interestingly, insulin levels also exhibit a nocturnal drop, which has previously been suggested to be controlled, at least in part, by melatonin. This regulation can be explained by the proposed inhibitory action of melatonin on insulin release. Indeed, both melatonin receptor 1A (MTNR1A) and MTNR1B are expressed in pancreatic islets. The role of melatonin in the regulation of glucose homeostasis has been highlighted by three independent publications based on genome-wide association studies of traits connected with type 2... (More)
Melatonin is a circulating hormone that is primarily released from the pineal gland. It is best known as a regulator of seasonal and circadian rhythms; its levels are high during the night and low during the day. Interestingly, insulin levels also exhibit a nocturnal drop, which has previously been suggested to be controlled, at least in part, by melatonin. This regulation can be explained by the proposed inhibitory action of melatonin on insulin release. Indeed, both melatonin receptor 1A (MTNR1A) and MTNR1B are expressed in pancreatic islets. The role of melatonin in the regulation of glucose homeostasis has been highlighted by three independent publications based on genome-wide association studies of traits connected with type 2 diabetes, such as elevated fasting glucose, and, subsequently, of the disease itself. The studies demonstrate a link between variations in the MTNR1B gene, hyperglycaemia, impaired early phase insulin secretion and beta cell function. The risk genotype predicts the future development of type 2 diabetes. Carriers of the risk genotype exhibit increased expression of MTNR1B in islets. This suggests that these individuals may be more sensitive to the actions of melatonin, leading to impaired insulin secretion. Blocking the inhibition of insulin secretion by melatonin may be a novel therapeutic avenue for type 2 diabetes. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Diabetologia
volume
52
pages
1240 - 1249
publisher
Springer Verlag
external identifiers
  • wos:000266496000004
  • pmid:19377888
  • scopus:67349224047
ISSN
1432-0428
DOI
10.1007/s00125-009-1359-y
language
English
LU publication?
yes
id
cc9cafa3-b545-4767-95b0-1bcd04e4a9f7 (old id 1391994)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19377888?dopt=Abstract
date added to LUP
2009-05-06 13:08:36
date last changed
2017-08-06 04:44:18
@article{cc9cafa3-b545-4767-95b0-1bcd04e4a9f7,
  abstract     = {Melatonin is a circulating hormone that is primarily released from the pineal gland. It is best known as a regulator of seasonal and circadian rhythms; its levels are high during the night and low during the day. Interestingly, insulin levels also exhibit a nocturnal drop, which has previously been suggested to be controlled, at least in part, by melatonin. This regulation can be explained by the proposed inhibitory action of melatonin on insulin release. Indeed, both melatonin receptor 1A (MTNR1A) and MTNR1B are expressed in pancreatic islets. The role of melatonin in the regulation of glucose homeostasis has been highlighted by three independent publications based on genome-wide association studies of traits connected with type 2 diabetes, such as elevated fasting glucose, and, subsequently, of the disease itself. The studies demonstrate a link between variations in the MTNR1B gene, hyperglycaemia, impaired early phase insulin secretion and beta cell function. The risk genotype predicts the future development of type 2 diabetes. Carriers of the risk genotype exhibit increased expression of MTNR1B in islets. This suggests that these individuals may be more sensitive to the actions of melatonin, leading to impaired insulin secretion. Blocking the inhibition of insulin secretion by melatonin may be a novel therapeutic avenue for type 2 diabetes.},
  author       = {Mulder, Hindrik and Nagorny, Cecilia and Lyssenko, Valeriya and Groop, Leif},
  issn         = {1432-0428},
  language     = {eng},
  pages        = {1240--1249},
  publisher    = {Springer Verlag},
  series       = {Diabetologia},
  title        = {Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene.},
  url          = {http://dx.doi.org/10.1007/s00125-009-1359-y},
  volume       = {52},
  year         = {2009},
}